David Lebowitz
Stock Analyst at Citigroup
(3.47)
# 854
Out of 5,182 analysts
119
Total ratings
60.92%
Success rate
14.38%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $71.78 | +17.02% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $60.69 | +38.41% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $33.23 | +44.45% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $12.24 | +63.40% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $222.08 | +30.58% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $97.74 | +5.38% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $32.39 | +17.32% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $36.34 | -39.46% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $69.71 | -3.89% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $44.93 | +24.64% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $13.20 | -24.24% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.21 | +23.97% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $70.26 | -35.95% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $94.06 | -27.71% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $516.69 | -26.07% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $53.30 | +80.11% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $5.23 | +129.45% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $302.11 | -45.72% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $23.32 | +67.24% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $21.11 | -0.52% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $8.60 | +4,609.30% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $4.20 | +233.33% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $71.78
Upside: +17.02%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $60.69
Upside: +38.41%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $33.23
Upside: +44.45%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $12.24
Upside: +63.40%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $222.08
Upside: +30.58%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $97.74
Upside: +5.38%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $32.39
Upside: +17.32%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $36.34
Upside: -39.46%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $69.71
Upside: -3.89%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $44.93
Upside: +24.64%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $13.20
Upside: -24.24%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.21
Upside: +23.97%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $70.26
Upside: -35.95%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $94.06
Upside: -27.71%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $516.69
Upside: -26.07%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $53.30
Upside: +80.11%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $5.23
Upside: +129.45%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $302.11
Upside: -45.72%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $23.32
Upside: +67.24%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $21.11
Upside: -0.52%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $8.60
Upside: +4,609.30%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $4.20
Upside: +233.33%